Shattuck Labs (STTK) Operating Margin (2019 - 2025)
Shattuck Labs (STTK) reported Operating Margin of 1071.6% for Q3 2025, down 47367.0% year-over-year from N/an in Q3 2024, and down 79.22% quarter-over-quarter from 597.93% in Q3 2024.
Shattuck Labs (STTK) Operating Margin (2019 - 2025) Analysis & Trends
Shattuck Labs (STTK) has 7 years of Operating Margin data on file, last reported at 1071.6% in Q3 2025.
- Operating Margin for Q3 2025 came in at 1071.6%, down 47367.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5266.4% (down 364000.0% YoY), and the FY2025 annual result was 5150.8%, down 374253.0% from the prior year.
- Operating Margin slipped to 1071.6% in Q3 2025 per STTK's latest filing, from 597.93% in the prior quarter.
- Over five years, Operating Margin peaked at 30.87% in Q4 2021 and troughed at 55316.0% in Q2 2022.
- A 5-year average of 9137.83% and a median of 1797.67% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin plunged 5473666 bps in 2022, then surged 4394250 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 30.87% in 2021, then plunged by 21929 bps to 6737.44% in 2022, then surged by 61 bps to 2654.2% in 2023, then jumped by 77 bps to 597.93% in 2024, then slumped by 79 bps to 1071.6% in 2025.
- Business Quant data shows STTK's Operating Margin at 1071.6% in Q3 2025, 597.93% in Q3 2024, and 1427.1% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Shattuck Labs | 190.32 Mn | 190.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,071.60% |
| Sep 30, 2024 | -597.93% |
| Jun 30, 2024 | -1,427.10% |
| Mar 31, 2024 | -1,797.67% |
| Dec 31, 2023 | -2,654.20% |
| Sep 30, 2023 | -4,168.80% |
| Jun 30, 2023 | -11,373.50% |
| Mar 31, 2023 | -38,001.75% |
| Dec 31, 2022 | -6,737.44% |
| Sep 30, 2022 | -11,900.47% |
| Jun 30, 2022 | -55,316.00% |
| Dec 31, 2021 | 30.87% |
| Sep 30, 2021 | -925.26% |
| Jun 30, 2021 | -579.34% |
| Mar 31, 2021 | -547.27% |
| Dec 31, 2020 | -895.01% |
| Sep 30, 2020 | -486.20% |
| Jun 30, 2020 | -198.68% |
| Mar 31, 2020 | -227.18% |
| Dec 31, 2019 | -270.26% |